Our innovative and elegant Technology platform for detecting and monitoring disease, including its treatment.

Current approaches rely on signals that scale with tumour burden. This is like finding a needle in a haystack especially during early stages of cancer. 

Instead, we profile the host immune response to tumour development which is known to be stronger for early stages of cancer.

Approaches such as ctDNA have not performed well at detecting cancer earlier. ctDNA is being investigated to assess on-treatment response i.e., after a patient is administered a drug.

 We disrupt by aiming to predict treatment response before a patient is prescribed a drug.

Imaging such as CT scans are usually relied upon to monitor progression of cancer. These scans also expose patients to radiation, limiting the frequency of use.

Over time patients that initially respond to a drug may acquire resistance to a drug. We provide a minimally invasive approach to monitor for acquired resistance to drugs, with the potential to impact dosage and efficacy.